DNA Sequencing Market Size, Share, and Trends 2024 to 2034

DNA Sequencing Market (By Product: Instruments, Consumables, and Services; By Technology: Third Generation DNA Sequencing, Next-Generation Sequencing, and Sanger Sequencing; By Application: Clinical Investigation, Oncology, Forensics & Agrigenomics, Reproductive Health, HLA Typing, and Others; By End-Use: Clinical Research, Academic Research, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Others) - Global Market Size, Share, Trends Analysis, Segment Forecast, Regional Outlook 2024 - 2034

  • Last Updated : July 2024
  • Report Code : 1189
  • Category : Healthcare

DNA Sequencing Market Size and Companies

The global DNA sequencing market size was USD 11.13 billion in 2023, accounted for USD 12.79 billion in 2024, and is expected to reach around USD 51.31 billion by 2034, expanding at a CAGR of 14.9% from 2024 to 2034. The North America DNA sequencing market size reached USD 5.68 billion in 2023.

DNA Sequencing Market Size 2024 to 2034

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

DNA Sequencing Market Key Takeaways

  • North America led the global market with the highest market share of 51% in 2023.
  • By Product, the Consumables segment has held the largest market share in 2023.
  • By Technology, the next-generation sequencing segment captured the biggest revenue share in 2023.
  • By Application, the Oncology segment captured the biggest revenue share in 2023.
  • By End-Use, the Academic Research segment is estimated to hold the highest market share in 2023.

U.S. DNA Sequencing Market Size and Growth 2024 to 2034

The U.S. DNA sequencing market size was estimated at USD 3.98 billion in 2023 and is predicted to be worth around USD 18.75 billion by 2034, at a CAGR of 15.1% from 2024 to 2034.

U.S. DNA Sequencing Market Size 2024 to 2034

North America dominated the DNA sequencing market in 2023. North America is the leader in the DNA sequencing market due to several factors, including significant firms' ongoing technological development, strong R&D investment, and the availability of technologically advanced healthcare infrastructure. Research on cancer treatments and medication development is supported by several government programs in the U.S. and Canada. These nations are seeing rapid growth in the biotechnology sector, which is resulting in more alternatives for treatments and diagnostics.

Bar Chart 193439

Audacious objectives for the U.S. bioeconomy include figuring out the function of at least 80% of recently found genes and sequencing the genomes of one million microbial species in five years. The National Science Foundation in the United States has been investing in biotechnology for decades, allowing the utilization of living organisms to produce goods and services that benefit society and speeding up scientific discovery.

DNA Sequencing Market Share, By Region, 2023 (%)

The Canadian government is putting great effort into reviving the country's biomanufacturing industry in order to provide Canadians with effective and safe therapies. In order to strengthen Canada's vaccination, biotechnology, pharmaceuticals, and biomanufacturing capabilities, more than $2.1 billion has been committed since March 2020. The Strategic Innovation Fund (SIF) will receive a $23 million investment from the Honourable Mary Ng, Minister of Innovation, Science and Industry, International Trade and Economic Development, to support Edesa Biotech's $61 million project.

Asia Pacific is expected to grow at the fastest rate during the forecast period. Strategic business expansion is driven by international enterprises' expanding consumer base. Furthermore, in the Asia-Pacific area, the Indian market for DNA sequencing was increasing at the fastest rate, while the Chinese market had the biggest market share.

Bar Chart 334522

Leveraging the power of strategic collaborations and developing capacity nationwide, the Department of Biotechnology (DBT) of the Government of India is leading the charge in fostering biotechnological innovation and entrepreneurship. One hundred fifty firms have raised around INR 4,500 Cr in follow-up funding. The nation's bioeconomy, which was valued at $137 billion in 2023, is projected to grow to $300 billion by 2030.

Market Overview

The fast development of DNA sequencing technology is providing scientists with the capability to generate information about genetic variation and outlines of gene expression on an unparalleled scale. The DNA sequencing technology is expected to allow scientists in achieving accurate sequencing of whole human genomes within just a few years. This technology will become a routine tool for scientists and clinicians. Numerous sequencing platforms presently in development have the potential to present greater advances in resolution and throughput. The massively parallel sequencing technologies are at present altering almost all fields of genetics, and the field of pharmacogenomics will be no exemption. The most predominant application of the new sequencing technologies in the field of pharmacogenomics is the detection of novel genetic variations that might influence drug response.

DNA Sequencing Market Growth Factors

  • Increasing prevalence of cancer
  • Technological advances in next-generation sequencing technologies
  • Rising demand for precision medicine
  • Declining costs of sequencing
  • High investment in research and development

Market Scope

Report Highlights Details
Growth Rate from 2024 to 2034 CAGR of 14.9%
Market Size in 2023 USD 11.13 billion
Market Size in 2024 USD 12.79 billion
Market Size by 2034 USD 51.31 billion
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2023
Forecast Period 2024 to 2034
Segments Covered Product, technology, Application, and End Use
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Product Insights

The consumables segment held the largest share of the DNA sequencing market in 2023. A vast range of goods, including kits, reagents, and other supplies necessary for various sequencing technologies, are referred to as sequencing consumables when discussing DNA sequencing techniques. The need for these consumables has increased due to the continual advancements in genomics and sequencing methods. In particular, the need for specialized consumables has expanded due to the widespread use of next-generation sequencing (NGS) technology in clinical diagnosis, research, and personalized medicine. Prominent industry players provide a variety of products designed to be compatible with different sequencing systems. It is projected that as genomics plays an increasingly significant role in biomedical research and healthcare, the market for sequencing consumables will expand gradually. 

Technology Insights

The next-generation sequencing segment dominated the DNA sequencing market in 2023. In genomics research, next-generation sequencing (NGS) is a potent instrument. Millions of DNA fragments can be sequenced simultaneously by NGS, yielding comprehensive data on genome structure, genetic variants, gene activity, and behavioral changes in genes. The main goals of recent developments have been to improve data analysis, lower expenses, and sequence data more quickly and accurately. These developments have enormous potential to improve our understanding of diseases and tailored therapy by revealing fresh insights into genetics. 

Application Insights

The oncology segment held the largest share of the DNA sequencing market in 2023. Sequential sequencing is also very important in the study of cancer. Thousands of tumor tissue samples are being sequenced as part of projects like The Cancer Genome Atlas in an effort to identify the specific genetic abnormalities that promote the growth of different cancer types. Researchers can also follow the evolution of a cancer's genetic makeup through sequencing. Researchers want to understand how cancer responds to treatment and may develop resistance to it by, for example, sequencing the DNA of a tumor before and after treatment.

20 million new instances of cancer and 9.7 million cancer-related deaths are expected in 2022, according to WHO projections. Five years after receiving a cancer diagnosis, an estimated 53.5 million people would still be alive. At some point in their lives, one in five people will be affected by cancer. The illness claims the lives of about 1 in 9 males and 1 in 12 women. Lung cancer is the most frequent cancer, making up 12.4% of all new cases, with 2.5 million new cases worldwide. The following in incidence order were female breast cancer (2.3 million cases, 11.6%), colon cancer (1.9 million cases, 9.6%), stomach cancer (970,000 cases, 4.9%), and prostate cancer (1.5 million cases, 7.3%).

worldwide Cancer Cases and Death Rate

End-Use Insights

By end-use, the academic research segment dominated the DNA sequencing market in 2023. The methodical study of a research problem or scenario with the goal of finding facts to address the issue or find a solution is known as academic research. The increase of academic research is attributed to various factors, including government efforts and considerable expenditure in research and development in the field of DNA sequencing.

DNA Sequencing Market Companies

  • Agilent Technologies
  • Illumina, Inc.
  • QIAGEN
  • Perkin Elmer
  • Thermo Fisher Scientific
  • Hoffmann-La Roche Ltd.
  • Macrogen, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Myriad Genetics

Major Market Segments Covered:

By Product

  • Instruments
  • Consumables
  • Services

By Technology

  • Third Generation DNA Sequencing
  • Next-Generation Sequencing
  • Sanger Sequencing

By Application

  • Clinical Investigation
  • Oncology
  • Forensics & Agrigenomics
  • Reproductive Health
  • HLA Typing
  • Others

By End-Use

  • Clinical Research
  • Academic Research
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Others

By Geography

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • United Kingdom
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Southeast Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa

Frequently Asked Questions

The global DNA sequencing market size is expected to be worth around USD 51.31 billion by 2034 and was valued USD 11.13 billion in 2023.

The global DNA sequencing market is growing at a CAGR of 14.9% over forecast period 2024 to 2034.

North America dominated the global market with a market share of more than 51%.

Asia Pacific is anticipated to grow at the maximum CAGR of around 16% in the forecast period due to high incidence of viral disorders.

Oncology accounted for the largest revenue in the application segment. High prevalence of cancer in developing regions is the key reason for high market share of oncology.

Among the product segment, consumables are expected to dominate the overall market.

DNA Sequencing Market

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on DNA Sequencing Market 

5.1. COVID-19 Landscape: DNA Sequencing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global DNA Sequencing Market, By Product

8.1. DNA Sequencing Market, by Product, 2024-2034

8.1.1. Instruments

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Consumables

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Services

Chapter 9. Global DNA Sequencing Market, By Technology

9.1. DNA Sequencing Market, by Technology, 2024-2034

9.1.1. Third Generation DNA Sequencing

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Next-Generation Sequencing

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Sanger Sequencing

9.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global DNA Sequencing Market, By Application 

10.1. DNA Sequencing Market, by Application, 2024-2034

10.1.1. Clinical Investigation

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Oncology

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Forensics & Agrigenomics

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Reproductive Health

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. HLA Typing

10.1.5.1. Market Revenue and Forecast (2021-2034)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global DNA Sequencing Market, By End-Use 

11.1. DNA Sequencing Market, by End-Use, 2024-2034

11.1.1. Clinical Research

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Academic Research

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Biotechnology & Pharmaceutical Companies

11.1.3.1. Market Revenue and Forecast (2021-2034)

11.1.4. Hospitals & Clinics

11.1.4.1. Market Revenue and Forecast (2021-2034)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global DNA Sequencing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.6.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.6.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.7.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.8.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.6.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.7.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.8.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.6.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.7.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.8.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.5.4. Market Revenue and Forecast, by End-Use (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.6.4. Market Revenue and Forecast, by End-Use (2021-2034)

Chapter 13. Company Profiles

13.1. Agilent Technologies

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Illumina, Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. QIAGEN

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Perkin Elmer

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Hoffmann-La Roche Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Macrogen, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Bio-Rad Laboratories, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Oxford Nanopore Technologies Ltd.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Myriad Genetics

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

 

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client